Program
ulotaront
Also written as “SEP-363856”, “SEP-363856 75mg” and “SEP363856”.
Its studies are mostly in Schizophrenia · Generalized Anxiety Disorder · Depressive Disorder, Major · Parkinson Disease · Narcolepsy, led by 2 companies.
Drug pageSEP-363856: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 265 open or running | phase 3since Aug 26, 2019 | Oct 24, 2013 | Mar 2028phase 3 · NCT07225712 |
| Sumitomo Pharma | 40 open or running | phase 3since Mar 29, 2021 | Nov 22, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sumitomo Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 22, 2017First study: phase 1 study in SchizophreniaFirst studyNCT03370640 · 24 enrolled · Japan
- Mar 23, 2020Phase 1 study in SchizophreniaNCT04325737 · 13 enrolled · Japan
- Dec 19, 2020Named ulotarontINNProposed as its International Nonproprietary Name in WHO's List 124 · before, SEP-363856, SEP363856
- Mar 29, 2021Phase 3 study in SchizophreniaNCT04825860 · 83 enrolled · China, Japan, Philippines and more
- Apr 27, 2022Phase 3 study in SchizophreniaNCT05359081 · 68 enrolled · Japan
TargetBeta
“Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist”ChEMBL 37, by rule
Studies
All 4 Sumitomo Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05359081Schizophrenia · Japan | 3 | Terminated | Mar 21, 2024 | 68 |
| NCT04825860Schizophrenia · China, Japan, Philippines and more | 3 | Terminated | Oct 12, 2023 | 83 |
| NCT04325737Schizophrenia · Japan | 1 | Completed | Aug 7, 2020 | 13 |
| NCT03370640Schizophrenia · Japan | 1 | Completed | Sep 20, 2018 | 24 |
How it is read
Names in the registry
- “SEP-363856”, 24 entries
- “SEP-363856 75mg”, 2 entries
- “SEP363856”, 2 entries
- “SEP-363856 100mg”, 1 entry
- “SEP-363856 50mg”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 23 studies
- Generalized Anxiety Disorder, 4 studies
- Depressive Disorder, Major, 1 study
- Parkinson Disease, 1 study
- Narcolepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.